New Advances in Ovarian Cancer
New Advances in Ovarian Cancer
Epithelial ovarian cancer is the leading cause of death from gynecologic malignancy in the United States, with approximately 15,000 deaths per year. Platinum/taxane doublets have long been considered the standard treatment regimen for advanced-stage disease; however, recent studies have sought to improve on the outcome from this therapy. Intraperitoneal (IP) chemotherapy has been shown to yield superior progression-free survival (PFS) and overall survival (OS); however, logistical problems and toxicities have limited more widespread adoption. Recent studies have also suggested that a “dose-dense” schedule of paclitaxel in combination with carboplatin may result in improved outcomes, and the impact of biological therapies in the first-line setting is under active investigation. In the setting of recurrent disease, preliminary results suggest that novel doublet regimens such as carboplatin and pegylated liposomal doxorubicin may have similar activity to standard platinum/taxane doublets while carrying a reduced risk of allergic reactions. Additionally, targeted therapy remains an active area of investigation, with evidence of activity from agents such as PARP inhibitors, anti-angiogenics, and PI3 kinase inhibitors. Here, we review recent advances in our understanding of ovarian cancer and its treatment in both the newly diagnosed and recurrent settings.
Epithelial ovarian cancer is diagnosed in an estimated 21,550 women in the United States per year and was responsible for 14,600 deaths in 2009; this cancer remains the leading cause of death from gynecologic malignancy in the United States. The vast majority of cases are diagnosed at a late stage (FIGO stage III or IV); FIGO staging for ovarian cancer is as per Table 1, and initial cytoreductive surgery is recommended for patients who are surgical candidates, followed by adjuvant chemotherapy. Ovarian cancer is distinguished by initial chemotherapy sensitivity; the majority of ovarian cancers will demonstrate a high response rate (~75%-80%) to first-line platinum- and taxane-based chemotherapy. However, most patients subsequently have disease relapse within 12 to 18 months. Recent studies have introduced new perspectives on the potential cell of origin of presumed high-grade serous ovarian cancer, as well as new approaches towards management of both newly diagnosed and recurrent disease. In this article, we will review recent advances in our understanding of the pathogenesis and management of epithelial ovarian cancer.
The Distal Fallopian Tube as Site of Origin
The pathogenesis of epithelial ovarian carcinomas is varied depending on histology. Type 1 ovarian cancers encompass low-grade serous and endometrioid as well as mucinous subtypes, and often demonstrate mutations in KRAS, BRAF, or PTEN. In contrast, the majority of epithelial ovarian cancers are high-grade serous carcinomas that are frequently associated with mutations in TP53. A long-standing model of ovarian cancer pathogenesis has suggested that the repeated trauma and repair associated with ovulation contributes to the development of ovarian carcinoma from ovarian surface epithelial cells. However, the observation that there is a significantly increased percentage of fallopian tube lesions in high-risk patients undergoing prophylactic bilateral salpingo-oophorectomy has raised the question of whether a portion of serous pelvic tumors may originate from the fimbria of the fallopian tube. This distribution of fallopian tube lesions has prompted additional investigation. In one study, a "p53 signature," where small segments of normal-appearing fallopian tube epithelium demonstrated strong p53 immunohistochemistry, was identified; this was often associated with mutation of the TP53 gene. Additionally, TP53 mutations were detected in all of the tubal intraepithelial carcinomas (TICs) tested, and in one case, the same mutation was shared by a contiguous "p53 signature" and TIC. These results suggest that the fallopian tube should be considered as a possible field of origin for pelvic serous carcinomas, and investigation currently continues in this area.
Treatment for Newly Diagnosed Ovarian Cancer
Neoadjuvant Chemotherapy and Timing of Cytoreductive Surgery
The approach to treatment for newly diagnosed ovarian, fallopian tube, and primary peritoneal cancers has typically been the same. Since Griffiths demonstrated the presence of an inverse relationship between overall survival and residual size, aggressive cytoreductive surgery has played an important role in the initial management of these cancers, and current NCCN guidelines suggest that cytoreductive surgery be considered in the initial treatment of newly diagnosed ovarian cancer. However, recent results from the European Organisation for Research and Treatment of Cancer–Gynecologic Cancer Group (EORTC–GCG) and the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) examining the efficacy and outcomes of primary neoadjuvant chemotherapy has raised the question of when patients should ideally undergo cytoreductive surgery. In this study, 718 patients with stage IIIC or IV ovarian cancer were randomized to receive either primary debulking surgery followed by 6 cycles of IV platinum-based chemotherapy or 3 cycles of neoadjuvant IV chemotherapy, followed by interval debulking surgery and then an additional 3 cycles of IV chemotherapy. Optimal cytoreduction (defined as residual ≤1 cm) was achieved in 48% of patients receiving primary debulking surgery and 83% of patients who received neoadjuvant chemotherapy. Additionally, patients who underwent primary debulking surgery had higher rates of complications, including post-operative mortality (2.7% vs 0.6%), sepsis (8% vs 2%), and grade 3 or 4 hemorrhage (7% vs 4%). The study, which was powered for non-inferiority, demonstrated no difference in median OS (29 vs 30 months) or PFS (11 months in both groups). Based upon these results, the authors concluded that neoadjuvant chemotherapy should be considered, given the similar survival outcomes and the increased relative morbidity of primary debulking surgery. Of note, this study did not require that surgery be performed by gynecologic oncologists, which in prior studies has been shown to result in higher rates of optimal cytoreduction and improved survival outcomes. The final peer-reviewed publication of these results has not yet occurred, and there have been no changes to recommendations with regard to the timing of primary debulking surgery.
Intravenous (IV) Chemotherapy
Despite recent studies with IP chemotherapy (discussed later in this article), IV chemotherapy is commonly used in patients with newly diagnosed ovarian cancer and is the treatment of choice for patients with suboptimally cytoreduced (residual cancer >1 cm) disease, poor performance status, contraindications to IP chemotherapy, and/or who decline IP treatment. The standard IV regimen of platinum and paclitaxel was established in a study by McGuire et al. in 1996 in which 410 patients with suboptimally debulked stage III or IV disease were randomized to receive either IV cisplatin and cyclophosphamide or IV cisplatin and paclitaxel. Response rates were significantly higher in the paclitaxel-containing arm (73% vs 60%, P = .01), and OS was also significantly longer (38 months vs 24 months, P < .001). As subsequent trials have demonstrated that carboplatin can result in equal efficacy but less toxicity than cisplatin in this setting,  a carboplatin-based regimen (including paclitaxel) has been considered a standard of care for IV chemotherapy in advanced ovarian cancer.
Although the dosing of IV carboplatin/paclitaxel has typically been administered once every 21 days, a recently reported trial from Japan has suggested that a dose-dense regimen of weekly paclitaxel in combination with carboplatin given once every 3 weeks may improve outcomes. In this open-label phase III study, 637 patients were randomized to receive 6 cycles of either paclitaxel 180 mg/m2 and carboplatin AUC 6 dosed once every 21 days or "dose-dense" paclitaxel at 80 mg/m2 on days 1, 8, and 15 and carboplatin AUC 6 on day 1 of a 21-day cycle. Median PFS was longer in the dose-dense group (28.0 months vs 17.2 months, P = .0015), and OS at 3 years was also statistically superior in the dose-dense group (72.1% vs 65.1%, P = .03). Grade 3 or 4 anemia was more common in the dose-dense group, but other toxicities were similar between the two treatment arms. These results have raised the question of whether a dose-dense schedule should be considered for patients receiving first-line IV chemotherapy and could represent a new option for the treatment of appropriate patients with advanced ovarian, peritoneal, or fallopian tube cancer.
Other studies have sought to improve the outcomes observed with IV carboplatin and paclitaxel by adding additional drugs to a platinum-doublet backbone. Bookman et al conducted a 4,312-patient study of women with newly diagnosed, advanced ovarian cancer that encompassed 5 arms: 1) a control arm of IV carboplatin AUC 6 and paclitaxel 175 mg/m2 every 21 days × 8 cycles; 2) carboplatin AUC 5 and paclitaxel 175 mg/m2 on day 1 and gemcitabine 800 mg/m2 on days 1 and 8, every 21 days × 8 cycles; 3) carboplatin AUC 5 and paclitaxel 175 mg/m2 every 21 days × 8 cycles and pegylated liposomal doxorubicin 30 mg/m2 on day 1 during cycles 1, 3, 5, and 7; 4) carboplatin AUC 5 on day 3 and topotecan 1.25 mg/m2/d on days 1, 2, 3, every 21 days × 4 cycles, followed by carboplatin AUC 6 and paclitaxel 175 mg/m2 every 21 days × 4 cycles; and 5) carboplatin AUC 6 on day 8 and gemcitabine 1,000 mg/m2 on days 1 and 8, every 21 days × 4 cycles, followed by carboplatin AUC 6 and paclitaxel 175 mg/m2 × 4 cycles. There were no differences observed among the five arms with respect to PFS and OS; thus, additional drugs added to platinum/taxane or the use of different platinum doublets did not demonstrate any improvement in clinical outcome.
Similarly, results from the Gynecologic Cancer Intergroup (GCIG) study AGO-OVAR-9, which compared a regimen of 6 cycles of carboplatin, platinum, and gemcitabine against carboplatin and paclitaxel alone have also been presented, and no benefit was observed from addition of gemcitabine to the control regimen. More recently, preliminary results were presented from a phase III study comparing the combination of carboplatin and pegylated liposomal doxorubicin in the first-line setting from the Mulitcentre Italian Trials in Ovarian Cancer (MITO-2) study. Response rates to these regimens appeared to be similar between the two treatment arms, and the final PFS analysis is pending. Given the results of these studies, carboplatin/paclitaxel remains the standard of care doublet for newly diagnosed disease.
The role of biologic therapies in the first-line treatment of newly diagnosed ovarian cancer is under active exploration. Anti-angiogenic agents have demonstrated activity in the recurrent setting, and two trials are currently investigating whether the addition of bevacizumab to first-line treatment will improve clinical outcomes. The Gynecologic Oncology Group (GOG) has completed enrollment of a large randomized placebo-controlled phase III trial (GOG 218) investigating the benefit of concurrent and maintenance bevacizumab with carboplatin and paclitaxel in newly diagnosed ovarian cancer, and preliminary results from this trial were presented at the ASCO meeting in June 2010. Three arms are included in this trial: 1) IV carboplatin, paclitaxel, and placebo for 6 cycles, followed by maintenance placebo for 1 year; 2) IV carboplatin, paclitaxel, and bevacizumab for 6 cycles, followed by maintenance placebo for 1 year; and 3) IV carboplatin, paclitaxel, and bevacizumab for 6 cycles, followed by maintenance bevacizumab for 1 year. The primary endpoint for this study was PFS, with a statistical plan to analyze each of the bevacizumab-containing arms individually against the control arm. If both of the bevacizumab-containing arms demonstrated benefit compared to the control, the bevacizumab arms would be compared to one another. A total of 1,873 patients was accrued to this trial, with a median follow-up of 17.4 months. A significant difference in PFS of 14.1 months versus 10.3 months (P < .0001) was observed favoring Arm 3 (carboplatin/taxol/bevacizumab followed by 1 year of maintenance bevacizumab) as compared to the control arm (carboplatin/taxol alone). No difference was observed in PFS between Arm 2 (carboplatin/taxol/bevacizumab followed by 1 year of maintenance placebo) and the control arm. The study was not powered to observe differences in OS, but preliminary data collected at the time of final PFS analysis did not reveal any differences between the three arms (39.3 months for Arm 1 vs 38.7 months for Arm 2 vs 39.7 months for Arm 3). A second randomized open-label phase III trial (ICON7) comparing IV carboplatin and paclitaxel to a regimen of IV carboplatin, paclitaxel, and bevacizumab followed by bevacizumab maintenance in the same setting has also completed enrollment. Additional biological therapies are also being explored in combination with chemotherapy in the first-line setting, and enrollment has recently begun for a phase III study (AGO-OVAR-12) with the oral anti-angiogenic agent BIBF 1120 in combination with carboplatin and paclitaxel in patients with advanced epithelial ovarian cancer.
Intraperitoneal (IP) chemotherapy
The role and dosing of IP chemotherapy in newly diagnosed optimally debulked ovarian cancer remains an area of discussion. The most recent randomized phase III study, published in January 2006, compared a regimen of paclitaxel 135 mg/m2 IV over 24 hours day 1 and IV cisplatin 75 mg/m2 day 2 to a regimen of IV paclitaxel 135 mg/m2 IV over 24 hours day 1, IP cisplatin 100 mg/m2 day 2, and IP paclitaxel 60 mg/m2 day 8, and demonstrated significant benefits in PFS and OS, with an OS of 65.6 months in the IP/IV arm compared to 49.7 months in the IV arm (P = .03). These results were consistent with the findings of two prior randomized trials conducted in the United States that suggested survival benefits of IP therapy over IV therapy (summarized in Table 2)[20,21] and, based upon these, a clinical alert was issued by the National Cancer Institute (NCI) stating that IP chemotherapy should be considered and discussed with women who have newly diagnosed, optimally debulked, stage III disease.
Despite the above findings, adoption of IP chemotherapy as the standard of care for optimally cytoreduced stage III disease has been controversial. Logistical concerns regarding IP chemotherapy, including the 24-hour administration schedule for day 1 paclitaxel as well as the regimen's toxicities, have prevented more widespread adoption of IP chemotherapy. Additionally, some centers have modified the GOG 172 regimen to reduce toxicities and decrease technical difficulties. Given the equivalent efficacy and reduced toxicity of IV carboplatin in comparison with IV cisplatin, the feasibility and efficacy of IP carboplatin has also been investigated.[24,25]
To further address the effectiveness of IP chemotherapy against current standard regimens, as well as to assess the potential of IP carboplatin chemotherapy, the GOG is now enrolling a phase III trial comparing a modified IP/IV GOG 172 cisplatin/paclitaxel regimen with an IP carboplatin/weekly paclitaxel and with an IV carboplatin/weekly paclitaxel regimen. In addition, bevacizumab will be added to the chemotherapy regimen on cycle 2 of each arm, and all three arms will also entail a year of bevacizumab maintenance therapy. A schema for this study (GOG 252) can be seen in Figure 1.